Context: Interpretation of calcitonin measurement to predict the prognosis of medullary thyroid carcinoma (MTC) requires multiple measurements over an extended time period, making it an imperfect biomarker for evaluating prognosis or disease behavior. Single circulating cell-free DNA (cfDNA) values have been shown to be a valuable prognostic marker for several solid tumors. Objective: We tested the hypothesis that cfDNA containing the RET M918T mutation could be detected in the blood of patients with advanced MTC whose tumor harbored an M918T mutation and would be able to predict overall survival more reliably than calcitonin. Design: The level of cfDNA containing RET M918T mutation was measured in the plasma of patients with MTC via droplet digital polymerase chain reaction. Patients: Patients had a confirmed sporadic MTC diagnosis, a serum calcitonin measurement >100 pg/mL, and tumor tissue biopsy results providing RET M918T mutation status. There were 75 patients included in this study, 50 of whom harbored an RET M918T mutation by tissue biopsy. Results: RET M918T cfDNA was detected in 16 of 50 patients (32%) with a positive tissue biopsy. The detection of RET M918T cfDNA strongly correlated with worse overall survival and more accurately predicted a worse outcome than calcitonin doubling time. Conclusions: Liquid biopsy is able to detect RET M918T mutations in patient plasma with high specificity but low sensitivity. In patients with established somatic RET M918T mutations, the allelic fraction of circulating tumor DNA is prognostic for overall survival and may play a role in monitoring response to treatment.
Context: Interpretation of calcitonin measurement to predict the prognosis of medullary thyroid carcinoma (MTC) requires multiple measurements over an extended time period, making it an imperfect biomarker for evaluating prognosis or disease behavior. Single circulating cell-free DNA (cfDNA) values have been shown to be a valuable prognostic marker for several solid tumors. Objective: We tested the hypothesis that cfDNA containing the RETM918T mutation could be detected in the blood of patients with advanced MTC whose tumor harbored an M918T mutation and would be able to predict overall survival more reliably than calcitonin. Design: The level of cfDNA containing RETM918T mutation was measured in the plasma of patients with MTC via droplet digital polymerase chain reaction. Patients: Patients had a confirmed sporadic MTC diagnosis, a serum calcitonin measurement >100 pg/mL, and tumor tissue biopsy results providing RETM918T mutation status. There were 75 patients included in this study, 50 of whom harbored an RETM918T mutation by tissue biopsy. Results:RETM918T cfDNA was detected in 16 of 50 patients (32%) with a positive tissue biopsy. The detection of RETM918T cfDNA strongly correlated with worse overall survival and more accurately predicted a worse outcome than calcitonin doubling time. Conclusions: Liquid biopsy is able to detect RETM918T mutations in patient plasma with high specificity but low sensitivity. In patients with established somatic RETM918T mutations, the allelic fraction of circulating tumor DNA is prognostic for overall survival and may play a role in monitoring response to treatment.
Authors: Johannes A A Meijer; Saskia le Cessie; Wilbert B van den Hout; Job Kievit; Johannes W Schoones; Johannes A Romijn; Johannes W A Smit Journal: Clin Endocrinol (Oxf) Date: 2009-06-26 Impact factor: 3.478
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956
Authors: Steven I Sherman; Douglas O Clary; Rossella Elisei; Martin J Schlumberger; Ezra E W Cohen; Patrick Schöffski; Lori J Wirth; Milan Mangeshkar; Dana T Aftab; Marcia S Brose Journal: Cancer Date: 2016-08-15 Impact factor: 6.860
Authors: Sarah Y Boostrom; Clive S Grant; Geoffrey B Thompson; David R Farley; Melanie L Richards; Tanya L Hoskin; Ian D Hay Journal: Arch Surg Date: 2009-07
Authors: C Pupilli; P Pinzani; F Salvianti; B Fibbi; M Rossi; L Petrone; G Perigli; M L De Feo; V Vezzosi; M Pazzagli; C Orlando; G Forti Journal: J Clin Endocrinol Metab Date: 2013-06-20 Impact factor: 5.958
Authors: Lisanne F van Dessel; Nick Beije; Jean C A Helmijr; Silvia R Vitale; Jaco Kraan; Maxime P Look; Ronald de Wit; Stefan Sleijfer; Maurice P H M Jansen; John W M Martens; Martijn P Lolkema Journal: Mol Oncol Date: 2017-02-22 Impact factor: 6.603
Authors: Michelle D Williams; Junsheng Ma; Elizabeth G Grubbs; Robert F Gagel; Rozita Bagheri-Yarmand Journal: Am J Cancer Res Date: 2021-06-15 Impact factor: 6.166
Authors: Rozita Bagheri-Yarmand; Ramona Dadu; Lei Ye; Yaashmin Shiny Jebaraj; Jade A Martinez; Junsheng Ma; Rohinton S Tarapore; Joshua E Allen; Steven I Sherman; Michelle D Williams; Robert F Gagel Journal: Mol Cancer Ther Date: 2021-02-03 Impact factor: 6.009
Authors: Germana Rappa; Caterina Puglisi; Mark F Santos; Stefano Forte; Lorenzo Memeo; Aurelio Lorico Journal: Int J Mol Sci Date: 2019-03-05 Impact factor: 5.923